OS Therapies Incorporated
OSTX
$2.00
$0.189.89%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1,418.84% | 631.78% | -26.66% | -8.77% | -78.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 156.39% | 291.74% | -48.54% | -39.87% | -33.52% |
| Operating Income | -156.39% | -291.74% | 48.54% | 39.87% | 33.52% |
| Income Before Tax | -104.23% | -45.58% | 37.83% | 21.01% | 42.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -104.23% | -45.58% | 37.83% | 21.01% | 42.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -104.23% | -45.58% | 37.83% | 21.01% | 42.61% |
| EBIT | -156.39% | -291.74% | 48.54% | 39.87% | 33.52% |
| EBITDA | -156.27% | -293.83% | 48.56% | 39.93% | 33.51% |
| EPS Basic | -62.81% | 51.85% | 45.26% | 28.98% | 45.89% |
| Normalized Basic EPS | -0.23% | 51.12% | 44.58% | 29.29% | 46.37% |
| EPS Diluted | -62.81% | 51.85% | 45.26% | 28.98% | 45.89% |
| Normalized Diluted EPS | -0.23% | 51.12% | 44.58% | 29.29% | 46.37% |
| Average Basic Shares Outstanding | 103.74% | 197.71% | 12.19% | 11.71% | 7.01% |
| Average Diluted Shares Outstanding | 103.74% | 197.71% | 12.19% | 11.71% | 7.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |